442685-53-2 Usage
General Description
1H-Indole-1-carboxylic acid, 5-(broMoMethyl)-, 1,1-diMethylethyl ester is a chemical compound that belongs to the ester group. It is a derivative of 1H-indole-1-carboxylic acid and contains a bromomethyl group. 1H-Indole-1-carboxylic acid, 5-(broMoMethyl)-, 1,1-diMethylethyl ester is commonly used in organic synthesis and pharmaceutical research as a building block for the synthesis of various biologically active molecules. Additionally, it has potential applications in the development of new drugs and pharmaceutical products. Its 1,1-diMethylethyl ester group also provides stability and protection for the molecule in various chemical reactions. Overall, this chemical has versatile applications in the field of pharmaceuticals and organic chemistry.
Check Digit Verification of cas no
The CAS Registry Mumber 442685-53-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,2,6,8 and 5 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 442685-53:
(8*4)+(7*4)+(6*2)+(5*6)+(4*8)+(3*5)+(2*5)+(1*3)=162
162 % 10 = 2
So 442685-53-2 is a valid CAS Registry Number.
442685-53-2Relevant articles and documents
THERAPEUTIC COMPOUNDS AND METHODS TO TREAT INFECTION
-
, (2019/02/13)
Disclosed herein are compounds of formula I: or a salt thereof and compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods for treating or preventing a bacterial infection in an animal comprising administering to the animal a compound of formula I or a pharmaceutically acceptable salt thereof, alone or in combination with a bacterial efflux pump inhibitor.
SUBSTITUTED PYRIDINONES
-
, (2008/06/13)
Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, and R5 are defined herein. These compounds are useful for treating diseases and conditions caused or exacerbated by unregulated p38 MAP Kinase and/or TNF activity. Pharmaceutical compositions containing the compounds, methods of preparing the compounds and methods of treatment using the compounds are also disclosed.
